Belimumab – new treatment opportunities in systemic lupus erythematosus

Magdalena Szmyrka-Kaczmarek; Piotr Wiland

eISSN: 2084-9834
ISSN: 0034-6233

Reumatologia/Rheumatology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2012
vol. 50

Send email

Copy url:

abstract:

Review paper

Belimumab – new treatment opportunities in systemic lupus erythematosus

Magdalena Szmyrka-Kaczmarek

,

Piotr Wiland

Reumatologia 2012; 50, 4: 349–361

Online publish date: 2012/09/07

View full text Get citation

Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease which course is characterized by flares and remissions. Despite the progress in its therapy and longer lifespan of patients it still remains a disease of uncertain prognosis and prolonged therapy, including steroid treatment, carries a burden of many side effects. No new treatment have been accepted in SLE for the last 50 years. It has changed lately, as the first biologic treatment – belimumab, monoclonal antibody anty-BLyS – has been registered in SLE. Belimumab inhibits growth factor for B-lymphocytes and in the large clinical trials has proved safe and efficacious in the treatment of SLE. It is especially indicated in patients with active disease, with positive anti-dsDNA antibodies and low complement and dependent on steroids.

keywords:

belimumab, systemic lupus erythematosus

EVENTS/KONFERENCJE

BOOKS/KSIĄŻKI

Belimumab – new treatment opportunities in systemic lupus erythematosus

Magdalena Szmyrka-Kaczmarek , Piotr Wiland

belimumab, systemic lupus erythematosus

Magdalena Szmyrka-Kaczmarek

,

Piotr Wiland